Clinical Trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

Name: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes — clinical trial record (NCT07712562)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BMF

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label, Phase 1/2 basket study to evaluate the safety and efficacy of Dibotatug (DR-01) in adults with Bone Marrow Failure syndromes.

Protocol Amendment History 1 change

critical Primary endpoint(s) modified 2026-07-25

Trial Details

NCT Number	NCT07712562
Lead Sponsor	Dren Bio
Conditions	Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe Aplastic Anemia, Refractory, Non-severe Aplastic Anemia
Enrollment	60 participants
Start Date	2026-08
Primary Completion	2029-04 (estimated)
Study Completion	2030-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-24